Clinical trials: SARS-CoV2
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.
- Trial name
- NCT05249829
- Testing
- mRNA-1273.529, mRNA-1273, mRNA-1273.214
- Where
- 29 sites in United Kingdom
- Volunteers
- 3,548 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
Covid19
Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19
This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at…
- Trial name
- NCT04646031
- Testing
- T89 capsule
- Where
- United States
- Sponsor
- Tasly Pharmaceuticals, Inc.
COVID-19 SARS-CoV-2 Infection
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT06679140
- Testing
- ibuzatrelvir
- Where
- 256 sites in United States, Argentina and 17 more
- Volunteers
- 2,330 people
- Sponsor
- Pfizer
Respiratory Disease
QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study
This study will evaluate the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method
- Trial name
- NCT05733559
- Testing
- QIAstat-Dx® Respiratory Panel Plus (RPP)
- Where
- United Kingdom
- Volunteers
- 565 people
- Sponsor
- QIAGEN Gaithersburg, Inc
COVID-19, SARS-COV-2 Infection
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19.
- Trial name
- NCT07069309
- Testing
- BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
- Where
- 19 sites in United States
- Volunteers
- 774 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes.
- Trial name
- NCT05157243
- Testing
- Nitazoxanide, Vitamin Super-B Complex, Standard of Care
- Sponsor
- Romark Laboratories L.C.
SARS-CoV-2 Infection
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test)…
- Trial name
- SCORPIO-PEP (NCT05897541)
- Testing
- S-217622
- Where
- 178 sites in United States, Argentina and 3 more
- Volunteers
- 3,701 people, healthy volunteers welcome
- Sponsor
- Shionogi
SARS-CoV-2
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
- Trial name
- NCT06130345
- Testing
- SPIKEVAX
- Where
- United States
- Volunteers
- 15,196,685 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
COVID-19
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
- Trial name
- NCT05787418
- Testing
- HH-120 Nasal Spray
- Where
- 2 sites in China
- Volunteers
- 918 people
- Sponsor
- Huahui Health
Coronavirus Infections, Severe Acute Respiratory Syndrome
Household Transmission Investigation Study for COVID-19 in Tropical Regions
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed…
- Conditions
- Coronavirus Infections, Severe Acute Respiratory Syndrome, SARS-CoV Infection
- Trial name
- EPI-COVID-19 (NCT04328129)
- Testing
- Human biological samples
- Where
- 4 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID -19, Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus
- Trial name
- NCT07217639
- Testing
- Aptitude Medical Systems Respiratory Panel Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Aptitude Medical Systems
Covid19
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged…
- Trial name
- COVID-19 (NCT04863638)
- Testing
- 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Prevention of Infectious Disease Caused by SARS-CoV-2
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA
This survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the Scientific Research Group of the Ministry of Health, Labour and Welfare at the initial stage of administration…
- Trial name
- NCT05135455
- Where
- 6 sites in Japan
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR-VA (NCT05663957)
- Testing
- Evusheld
- Where
- United States
- Volunteers
- 5,814 people
- Sponsor
- AstraZeneca
SARS-CoV-2 Acute Respiratory Disease
Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19)
A multicenter study, using prospectively collected, fresh (Category I) and frozen (Category II), residual/leftover nasopharyngeal (NP) swab in UTM/UVT specimens obtained from symptomatic individuals suspected of COVID-19…
- Trial name
- NCT06360757
- Testing
- NeuMoDx SARS-CoV-2 Assay
- Where
- United Kingdom
- Volunteers
- 503 people
- Sponsor
- QIAGEN Gaithersburg, Inc
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness at UPMC
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR-C19 UPMC (NCT05667116)
- Testing
- EVUSHELD
- Where
- United States
- Volunteers
- 4,232 people
- Sponsor
- AstraZeneca
SARS-CoV2 Infection, COVID-19
COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation
SARS-CoV-2 rapid antigen over the counter clinical performance evaluation
- Trial name
- NCT05584176
- Testing
- iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
- Where
- 4 sites in United States
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- MP Biomedicals, LLC
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche